神经科指南

订阅

MedSci主页 / 所有栏目 / 神经科指南

2018 ESICM共识建议：神经重症监护患者液体治疗

2018-03-02 欧洲危重病医学会 Intensive Care Med. 2018 Mar 2.·

神经重症监护液体治疗

2018年3月，欧洲危重病医学会(ESICM)发布了神经重症监护患者液体治疗建议，液体治疗是神经重症监护室内基本组成部分，本文主要解决以下3个问题：1.神经重症监护室内一般液体治疗，高渗液体控制颅内压以及DIC的液体治疗。

中文标题：

2018 ESICM共识建议：神经重症监护患者液体治疗

英文标题：

Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations.

发布机构：

欧洲危重病医学会

发布日期：

2018-03-02

简要介绍：

2018年3月，欧洲危重病医学会(ESICM)发布了神经重症监护患者液体治疗建议，液体治疗是神经重症监护室内基本组成部分，本文主要解决以下3个问题：1.神经重症监护室内一般液体治疗，高渗液体控制颅内压以及DIC的液体治疗。

 

拓展指南：[神经|5]]

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 ESICM共识建议：神经重症监护患者液体治疗)] GetToolGuiderByIdResponse(projectId=1, id=13a2e1c00156a814, title=2018 ESICM共识建议：神经重症监护患者液体治疗, enTitle=Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations., guiderFrom=Intensive Care Med. 2018 Mar 2.·, authorId=null, author=, summary=2018年3月，欧洲危重病医学会(ESICM)发布了神经重症监护患者液体治疗建议，液体治疗是神经重症监护室内基本组成部分，本文主要解决以下3个问题：1.神经重症监护室内一般液体治疗，高渗液体控制颅内压以及DIC的液体治疗。 , cover=, journalId=null, articlesId=null, associationId=746, associationName=欧洲危重病医学会, associationIntro=欧洲危重病医学会于1982年在瑞士日内日瓦成立，是一个非营利性的国际联盟组织。主要致力于支持和推进重症监护医学知识的更新和进步。, copyright=0, guiderPublishedTime=Fri Mar 02 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年3月，欧洲危重病医学会(ESICM)发布了神经重症监护患者液体治疗建议，液体治疗是神经重症监护室内基本组成部分，本文主要解决以下3个问题：1.神经重症监护室内一般液体治疗，高渗液体控制颅内压以及DIC的液体治疗。 </P> <P> </P>拓展指南：[神经|5]], tagList=[TagDto(tagId=71279, tagName=神经重症监护), TagDto(tagId=20452, tagName=液体治疗)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7175, appHits=393, showAppHits=0, pcHits=5409, showPcHits=1967, likes=142, shares=14, comments=26, approvalStatus=1, publishedTime=Wed Mar 07 21:18:57 CST 2018, publishedTimeString=2018-03-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Mar 07 21:18:57 CST 2018, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 21:07:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 ESICM共识建议：神经重症监护患者液体治疗)])
2018 ESICM共识建议：神经重症监护患者液体治疗
下载请点击：
评论区 (25)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207134, encodeId=f4f6120e134a2, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:49:28 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317600, encodeId=c44831e600ed, content=学习了新的知识.新观点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:56 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317599, encodeId=77b731e599d1, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:38 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317598, encodeId=b86f31e598ce, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:19 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306255, encodeId=ab30306255e4, content=好文献.学习了好文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 16 07:07:46 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2022-03-30 洁巴子

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207134, encodeId=f4f6120e134a2, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:49:28 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317600, encodeId=c44831e600ed, content=学习了新的知识.新观点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:56 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317599, encodeId=77b731e599d1, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:38 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317598, encodeId=b86f31e598ce, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:19 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306255, encodeId=ab30306255e4, content=好文献.学习了好文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 16 07:07:46 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-05-22 122d45d1m57(暂无昵称)

    学习了新的知识.新观点

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207134, encodeId=f4f6120e134a2, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:49:28 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317600, encodeId=c44831e600ed, content=学习了新的知识.新观点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:56 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317599, encodeId=77b731e599d1, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:38 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317598, encodeId=b86f31e598ce, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:19 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306255, encodeId=ab30306255e4, content=好文献.学习了好文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 16 07:07:46 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-05-22 122d45d1m57(暂无昵称)

    干货

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207134, encodeId=f4f6120e134a2, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:49:28 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317600, encodeId=c44831e600ed, content=学习了新的知识.新观点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:56 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317599, encodeId=77b731e599d1, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:38 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317598, encodeId=b86f31e598ce, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:19 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306255, encodeId=ab30306255e4, content=好文献.学习了好文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 16 07:07:46 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-05-22 122d45d1m57(暂无昵称)

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1207134, encodeId=f4f6120e134a2, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:49:28 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317600, encodeId=c44831e600ed, content=学习了新的知识.新观点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:56 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317599, encodeId=77b731e599d1, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:38 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317598, encodeId=b86f31e598ce, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=324c2362330, createdName=122d45d1m57(暂无昵称), createdTime=Tue May 22 21:30:19 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306255, encodeId=ab30306255e4, content=好文献.学习了好文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 16 07:07:46 CST 2018, time=2018-04-16, status=1, ipAttribution=)]
    2018-04-16 张新亮1853311252142e2fm

    好文献.学习了好文献.学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

NCS：2015癫痫持续状态的评估和管理指南

美国神经重症监护学会(NCS,Neurocritical Care Society) · 2015-04-05